Tumor mutational burden (TMB) and BCG responsiveness in high-risk non-muscle invasive bladder cancer (NMIBC).

被引：2
|
作者：
Bastos, Diogo Assed
Lima, Mariana
Mattedi, Romulo Loss
dos Santos, Filipe Ferreira
Buzatto, Vanessa
Barreiro, Rodrigo
Ribeiro-Filho, Leopoldo
Cordeiro, Mauricio
Amano, Mariane
Souza, Jussara Michaloski
Bettoni, Fabiana
Favoretto Galante, Pedro Alexandre
Dzik, Carlos
Nahas, William Carlos
Camargo, Anamaria Aranha
机构：
[1] Hosp Sirio Libanes, Sao Paulo, Brazil
[2] Inst Canc Estado Sao Paulo, Sao Paulo, Brazil
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 07期
关键词：
D O I：
10.1200/JCO.2019.37.7_suppl.442
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
442
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Tumor mutational burden (TMB), intratumoral genetic heterogeneity (ITGH) and BCG responsiveness in high-risk non-muscle invasive bladder cancer (NMIBC).
    Bastos, Diogo Assed
    Lima, Mariana
    Mattedi, Romulo Loss
    Dzik, Carlos
    Ribeiro-Filho, Leopoldo
    Cordeiro, Mauricio
    Nahas, William Carlos
    Souza, Jussara Michaloski
    Amano, Mariane
    Bettoni, Fabiana
    Buzatto, Vanessa
    dos Santos, Filipe Ferreira
    Barreiro, Rodrigo
    Favoretto Galante, Pedro Alexandre
    Camargo, Anamaria Aranha
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] HIGH-RISK NMIBC (NON-MUSCLE INVASIVE BLADDER CANCER): PROGNOSTIC VALUE OF CIRCULATING TUMOR CELLS
    De Berardinis, Ettore
    Busetto, Gian Maria
    Petracce, Arianna
    Nicolazzo, Chiara
    Gazzaniga, Paola
    Gentile, Vincenzo
    JOURNAL OF UROLOGY, 2011, 185 (04): : E205 - E206
  • [3] Combination therapy in high-risk non-muscle invasive bladder cancer (HR-NMIBC) with and without BCG prior treatment
    Rexer, H.
    Ohlmann, C. -H.
    Grimm, M. -O.
    UROLOGIE, 2023, 62 (03): : 338 - 339
  • [4] Association of BCG shortage with bladder cancer recurrence in high-risk non-muscle invasive bladder cancer
    Lee, Sangmin
    Lim, Bumjin
    You, Dalsan
    Song, Cheryn
    Hong, Bumsik
    Hong, Jun Hyuk
    Ahn, Hanjong
    Kim, Choung-Soo
    Jeong, In Gab
    INTERNATIONAL JOURNAL OF UROLOGY, 2020, 27 : 26 - 27
  • [5] Current treatments for BCG failure in non-muscle invasive bladder cancer (NMIBC)
    Alvarez-Maestro, M.
    Guerrero-Ramos, F.
    Rodriguez-Faba, O.
    Dominguez-Escrig, J. L.
    Fernandez-Gomez, J. M.
    ACTAS UROLOGICAS ESPANOLAS, 2021, 45 (02): : 93 - 102
  • [6] Tumor mutation burden to predict progression in high-risk non-muscle invasive bladder cancer.
    Meeks, Joshua
    Carneiro, Benedito A.
    Pai, Sachin Gopalkrishn
    Oberlin, Daniel
    Rademaker, Alfred
    Fedorchak, Kyle
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [7] Patterns of treatment of high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients among Arab urologists
    Moussa, Mohamad
    Chakra, Mohamad Abou
    Shore, Neal D.
    Papatsoris, Athanasios
    Farahat, Yasser
    ODonnell, Michael A.
    ARCHIVIO ITALIANO DI UROLOGIA E ANDROLOGIA, 2024, 96 (01)
  • [8] BENEFITS AND COSTS OF ALTERNATIVE GUIDELINES FOR SURVEILLANCE OF HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC)
    Su, Zhuo T.
    Mahon, Katherine
    Rezaee, Michael
    Patel, Sunil
    Townsend, Jeffrey
    Kates, Max
    JOURNAL OF UROLOGY, 2024, 211 (05): : E1169 - E1170
  • [9] Management of high-risk non-muscle invasive bladder cancer
    Brausi, M.
    Olaru, V.
    MINERVA UROLOGICA E NEFROLOGICA, 2012, 64 (04) : 255 - 260
  • [10] Biomedical markers of response to intravesical BCG treatment in high-risk non-muscle invasive bladder cancer
    Jallad, S.
    Thomas, P.
    Newport, M.
    Kern, F.
    BRITISH JOURNAL OF SURGERY, 2014, 101 : 66 - 67
12345